SAN

78.22

+2.53%↑

ARGX

762.4

+4.73%↑

SHL.DE

34.82

+0.29%↑

PHIA

22.78

+1.92%↑

FRE

37.35

+2.47%↑

SAN

78.22

+2.53%↑

ARGX

762.4

+4.73%↑

SHL.DE

34.82

+0.29%↑

PHIA

22.78

+1.92%↑

FRE

37.35

+2.47%↑

SAN

78.22

+2.53%↑

ARGX

762.4

+4.73%↑

SHL.DE

34.82

+0.29%↑

PHIA

22.78

+1.92%↑

FRE

37.35

+2.47%↑

SAN

78.22

+2.53%↑

ARGX

762.4

+4.73%↑

SHL.DE

34.82

+0.29%↑

PHIA

22.78

+1.92%↑

FRE

37.35

+2.47%↑

SAN

78.22

+2.53%↑

ARGX

762.4

+4.73%↑

SHL.DE

34.82

+0.29%↑

PHIA

22.78

+1.92%↑

FRE

37.35

+2.47%↑

Kodu・Aktsiate loetelu・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Suletud

SektorTervishoid

58.85 -0.08

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

58.8

Max

59.5

Põhinäitajad
By Trading Economics
Sissetulek	-33M 9.5M
Müük	-66M 152M
P/E Sektori keskmine	24.47 49.888
Aktsiakasum	0.185
Kasumimarginaal	6.216
Töötajad	1,950
EBITDA	-45M 18M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+27.89% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	23. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-1.1B 3B
Eelmine avamishind	58.93
Eelmine sulgemishind	58.85

Uudiste sentiment

By Acuity

50%

155 / 344 Pingereas Healthcare

Laboratorios Farmaceuticos Rovi SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. juuni 2026, 21:51 UTC

Suurimad hinnamuutused turgudel

Merlin Shares Rally After Defense Department's Design Review Wraps

4. juuni 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4. juuni 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4. juuni 2026, 23:42 UTC

Omandamised, ülevõtmised, äriostud

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4. juuni 2026, 23:41 UTC

Omandamised, ülevõtmised, äriostud

Energy Resources of Australia to Enter Trading Halt

4. juuni 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4. juuni 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. juuni 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4. juuni 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4. juuni 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4. juuni 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. juuni 2026, 20:44 UTC

Omandamised, ülevõtmised, äriostud

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4. juuni 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4. juuni 2026, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4. juuni 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4. juuni 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4. juuni 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4. juuni 2026, 18:47 UTC

Omandamised, ülevõtmised, äriostud

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4. juuni 2026, 18:38 UTC

Tulu

Money Quote: Tech Weakness in Context -- WSJ

4. juuni 2026, 18:24 UTC

Tulu

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4. juuni 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4. juuni 2026, 16:58 UTC

Tulu

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4. juuni 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4. juuni 2026, 16:38 UTC

Tulu

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4. juuni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4. juuni 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4. juuni 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4. juuni 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4. juuni 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Laboratorios Farmaceuticos Rovi SA Prognoos

Hinnasiht

By TipRanks

27.89% tõus

12 kuu keskmine prognoos

Keskmine 73.6 EUR 27.89%

Kõrge 83 EUR

Madal 64.2 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Laboratorios Farmaceuticos Rovi SA aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

155 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.